ROSEN, SKILLED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Class Action Details - The class action lawsuit is for purchasers of MoonLake common stock between March 10, 2024, and September 29, 2025, inclusive [1]. - Investors who purchased stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. Group 3: Allegations Against MoonLake - The complaint alleges that MoonLake made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically concerning molecular targets and clinical benefits [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the company [5].